Rotavirus vaccination techniques have become a component of a comprehensive worldwide public health effort to combat rotavirus-associated gastroenteritis, particularly in babies and children in poor countries. Several investigations on the effectiveness of various rotavirus vaccination dosage regimens have yielded conflicting results. As a result, a systematic review of the published literature on rotavirus vaccination dosing schedules using the live attenuated RV1 rotavirus vaccine in infants and children was conducted, including randomized controlled clinical trials (RCTs) published between January 1998 and January 2018, with a meta-analysis of the published data. The first examination yielded 495 papers, three of which met the selection eligibility requirements. Three studies comparing RV1 rotavirus vaccine immunogenicity compared a two-dose immunization regimen to a three-dose vaccination schedule. When compared to a two-dose vaccination schedule, the adoption of a three-dose vaccination schedule did not result in a statistically significant seroconversion rate. The three-dose vaccination schedule did not result in substantially higher geometric mean concentrations (GMCs) compared to the two-dose vaccination schedule, according to an analysis of included studies with one-month follow-up time.
Rotavirus immunogenicity did not rise significantly with the three-dose plan at 6, 10, and 14 weeks, but did increase with the two-dose schedule at 10 and 14 weeks. These findings suggest that further controlled studies should be conducted to support the most successful and cost-efficient rotavirus vaccination regimens, particularly for babies and children in impoverished countries.